References

British National Formulary. Type two diabetes. 2022. https://bnf.nice.org.uk/treatment-summary/type-2-diabetes.html (Accessed 11 August 2022)

Healthy weight, healthy lives: one year on.London2009

Diabetes UK. Diabetes statistics. 2021. https://www.diabetes.org.uk/professionals/position-statements-reports/statistics (Accessed 11 August 2022)

Diabetes UK. Diabetes facts and figures. 2020. https://www.diabetes.org.uk/professionals/position-statements-reports/statistics (Accessed 11 August 2022)

Diabetes UK. Facts and statistics. 2019. https://www.diabetes.org.uk/resources-s3/2019-11/facts-stats-update-oct-2019.pdf (Accessed 11 August 2022)

Adverse Effects of GLP-1 Receptor Agonists. 2014. https://doi.org/10.1900/rds.2014.11.202

Age-specific trends from 2000-2011 in all-cause and cause-specific mortality in type 1 and type 2 diabetes: a cohort study of more than one million people. 2016. https://doi.org/10.2337/dc15-2308

Hypoglycaemia in older home-dwelling people with diabetes-a scoping review. 2021. https://doi.org/10.1186/s12877-020-01961-6

Increase in the Incidence of Diabetes and Its Implications. 2017. https://doi.org/10.1056/nejme1616575

International Diabetes Federation. IDF Diabetes Atlas. 2021. https://diabetesatlas.org (Accessed 11 August 2022)

Effects of dietary and physical activity interventions on the risk of type 2 diabetes in South Asians: meta-analysis of individual participant data from randomised controlled trials. 2019. https://doi.org/10.1007/s00125-019-4905-2

Sex differences in human adipose tissues - the biology of pear shape. 2012. https://doi.org/10.1186/2042-6410-3-13

Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. 2016. https://doi.org/10.1210/er.2015-1137

Obesity prevalence among healthcare professionals in England: a cross-sectional study using the Health Survey for England. 2017. https://openresearch.lsbu.ac.uk/download/690c265926642aa29e363ba985e0bc6bb00ebf8e89d56634bcc6363ca7cbf178/357831/e018498.full.pdf

Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. 2018. https://doi.org/10.1016/s0140-6736(17)33102-1

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. 2016. https://doi.org/10.1136/bmj.i610

The diabetes risk score: a practical tool to predict type 2 diabetes risk. 2003. https://doi.org/10.2337/diacare.26.3.725

Young-onset type 2 diabetes mellitus - implications for morbidity and mortality. 2020. https://doi.org/10.1038/s41574-020-0334-z

CARMELINA Investigators. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. 2019. https://doi.org/10.1161/circulationaha.118.038352

Optimal glycaemic control in elderly people with type 2 diabetes: what does the evidence say?. 2015. https://doi.org/10.1007/s40264-014-0247-7

Medline Plus. Hemoglobin a1c (Hba1c). 2021. https://medlineplus.gov/lab-tests/hemoglobin-a1c-hba1c-test/

Metabolic alterations in middle-aged and elderly obese patients with type 2 diabetes. 1999. https://doi.org/10.2337/diacare.22.1.112

NHS England. Thousands to benefit from soups and shakes diet on the NHS from today. 2020. http://www.england.nhs.uk/2020/09/thousands-to-benefit-from-soups-and-shakes-diet-on-the-nhs-from-today/

NHS England. Low calorie diets to treat obesity and Type 2 diabetes. 2021. http://www.england.nhs.uk/diabetes/treatment-care/low-calorie-diets/ (Accessed 11 August 2022)

NHS London. Consensus Approach to the Diagnosis of Type 2 Diabetes. 2018. https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2019/07/dia-consensus-type2-27092018-FINAL.pdf (Accessed 11 August 2022)

National Institute for Health and Care Excellence. Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups. 2018. https://www.nice.org.uk/guidance/QS167 (Accessed 11 August 2022)

National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. 2022a. https://www.nice.org.uk/guidance/ng28 (Accessed 11 August 2022)

National Institute for Health and Care Excellence. Diabetes - type 2: DPP-4 inhibitors. 2022b. https://cks.nice.org.uk/topics/diabetes-type-2/prescribing-information/dpp-4-inhibitors/ (Accessed 11 August 2022)

National Institute for Health and Care Excellence. Diabetes - type 2: Sulfonylureas. 2022c. https://cks.nice.org.uk/topics/diabetes-type-2/prescribing-information/sulfonylureas/ (Accessed 11 August 2022)

National Institute for Health and Care Excellence. GLP-1 receptor agonists. 2022d. https://cks.nice.org.uk/topics/diabetes-type-2/prescribing-information/glp-1-receptor-agonists/ (Accessed 11 August 2022)

National Institute for Health and Care Excellence. Pioglitiazone. 2022d. https://bnf.nice.org.uk/drug/pioglitazone.html (Accessed 11 August 2022)

National Institute for Health and Care Excellence. NICE recommends new drug for people living with obesity. 2022e. https://www.nice.org.uk/news/article/nice-recommends-new-drug-for-people-living-with-obesity (Accessed 11 August 2022)

Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review. 2019. https://doi.org/10.1111/dom.13550

User's guide to mechanism of action and clinical use of GLP-1 receptor agonists. 2015. https://doi.org/10.1080/00325481.2015.1090295

Singh G, Can AS, Correa R Pioglitazone.Treasure Island (FL): StatPearls Publishing; 2022

Skugor M Chapter 14. Elsevier LifeSciences. 2018; 1055-1060

Sulfonylureas and their use in clinical practice. 2015. https://doi.org/10.5114/aoms.2015.53304

Diabetes, cardiovascular disease and the microcirculation. 2018. https://doi.org/10.1186/s12933-018-0703-2

Brain changes in overweight/obese and normal-weight adults with type 2 diabetes mellitus. 2017. https://doi.org/10.1007/s00125-017-4266-7

Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia. 2015. https://doi.org/10.2337/dc14-0599

The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. 2015. https://doi.org/10.1146/annurev-med-051013-110046

Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression. 2020. https://doi.org/10.1016/s2213-8587(19)30405-x

Microvascular complications: pathophysiology and management. 2010. https://doi.org/10.7861/clinmedicine.10-5-505

Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis of randomized controlled trials. 2017. https://doi.org/10.1097/md.0000000000006944

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. 2019. https://doi.org/10.1016/S0140-6736(18)32590-X

Type 2 diabetes: an update for community nurses

02 September 2022
Volume 27 · Issue 9

Abstract

There are now over four million people living with diabetes in the UK, the majority having type 2 diabetes. The prevalence of type 2 diabetes is rising in line with growing obesity levels. This article will explore prevalence of type 2 diabetes, its prevention and treatment. It also provides guidance on how nurses can work with people at risk of diabetes, to prevent it, induce remission and create awareness of medications used to treat it.

Diabetes is a chronic, metabolic disease characterised by elevated levels of blood glucose (or blood sugar), which over time, can lead to serious damage to the heart, blood vessels, eyes, kidneys and nerves. Type 1 diabetes, once known as juvenile diabetes or insulin-dependent diabetes, is a chronic condition in which the pancreas produces little to no insulin by itself. However, the most common type is type 2 diabetes, usually seen in adults, which occurs when the body becomes resistant to insulin or doesn't produce enough of it. In the past 3 decades, the prevalence of type 2 diabetes has risen dramatically in countries of all income levels (WHO, 2021a).

In the UK, and globally, the prevalence of type 2 diabetes has risen in line with growing obesity levels (WHO, 2021a: WHO, 2021b). In the UK, diabetes mellitus (DM) affects 7.4% of the population but 15% of those with severe mental illness (Diabetes UK, 2021; Public Health England, 2018). Figure 1 illustrates the increasing numbers of people in the UK with diabetes (Diabetes UK, 2021).

Register now to continue reading

Thank you for visiting Community Nursing and reading some of our peer-reviewed resources for district and community nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month